Home Companies Upsher-Smith COMPANY
Status: Acquired, now part of Bora Pharmaceuticals · How status works
FDA-cleared device company Clinical Phase 3
1 open job · last seen Oct 23, 2026 · 6 sources
Location: Maple Grove, MN · source · Oct 15, 2026
Profile checked Oct 10, 2026
Keywords: Epilepsy Migraine Disorders Male Hypogonadism Migraine Headaches Postmenopausal Symptoms USL255 Vogelxo Divigel Show all 8 keywords
At a glance HQ Maple Grove, MN source Stage FDA-cleared device company Clinical Phase 3 Latest trial Phase 4: Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old (Feb 19, 2021) source Timeline Feb 19, 2021 Trial start Phase 4: Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old source ↗ Aug 28, 2020 Trial start Phase 4: Vogelxo(R) ABPM Study in Hypogandal Men source ↗ Jul 11, 2016 Trial start Phase 2: An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg) source ↗ 2010-10 Trial start Phase 3: Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures source ↗ 2010-05 Trial start Phase 3: Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures source ↗ 2004-07 Trial start Phase 3: Study to Evaluate Divigel for the Treatment of Postmenoupausal Symptoms source ↗ Clinical trials (lead sponsor) 6 Record Title Phase Status Start Primary completion NCT04748601 Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old Phase 4 Recruiting Feb 19, 2021 2026-09 (estimated) NCT04558567 Vogelxo(R) ABPM Study in Hypogandal Men Phase 4 Completed Aug 28, 2020 Dec 12, 2023 (actual) NCT02856802 An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg) Phase 2 Completed Jul 11, 2016 Feb 10, 2017 (actual) NCT01191086 Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures Phase 3 Completed 2010-10 2014-05 (actual) NCT01142193 Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures Phase 3 Completed 2010-05 2012-12 (actual) NCT00727129 Study to Evaluate Divigel for the Treatment of Postmenoupausal Symptoms Phase 3 Completed 2004-07 Not listed
Open jobs 1 Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
